PMID- 24115841
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20211021
IS  - 1178-6264 (Print)
IS  - 1178-6264 (Electronic)
IS  - 1178-6264 (Linking)
VI  - 2008
DP  - 2008 Jul 22
TI  - Targeted Cancer Therapy with Tumor Necrosis Factor-Alpha.
PG  - 15-21
AB  - Tumor necrosis factor-alpha (TNF-alpha), a member of the TNF superfamily, was the 
      first cytokine to be evaluated for cancer biotherapy. However, the clinical use 
      of TNF-alpha is severely limited by its toxicity. Currently, TNF-alpha is administered 
      only through locoregional drug delivery systems such as isolated limb perfusion 
      and isolated hepatic perfusion. To reduce the systemic toxicity of TNF-alpha, various 
      strategies have been explored over the last several decades. This review 
      summarizes current state-of-the-art targeted cancer therapy using TNF-alpha. Passive 
      targeting, cell-based therapy, gene therapy with inducible or tissue-specific 
      promoters, targeted polymer-DNA complexes, tumor pre-targeting, antibody-TNF-alpha 
      conjugate, scFv/TNF-alpha fusion proteins, and peptide/TNF-alpha fusion proteins have all 
      been investigated to combat cancer. Many of these agents are already in advanced 
      clinical trials. Molecular imaging, which can significantly speed up the drug 
      development process, and nanomedicine, which can integrate both imaging and 
      therapeutic components, has the potential to revolutionize future cancer patient 
      management. Cooperative efforts from scientists within multiple disciplines, as 
      well as close partnerships among many organizations/entities, are needed to 
      quickly translate novel TNF-alpha-based therapeutics into clinical investigation.
FAU - Cai, Weibo
AU  - Cai W
AD  - Departments of Radiology and Medical Physics, School of Medicine and Public 
      Health, University of Wisconsin-Madison, Madison, Wisconsin, U.S.A. ; University 
      of Wisconsin Paul P. Carbone Comprehensive Cancer Center, Madison, Wisconsin, 
      U.S.A.
FAU - Kerner, Zachary J
AU  - Kerner ZJ
FAU - Hong, Hao
AU  - Hong H
FAU - Sun, Jiangtao
AU  - Sun J
LA  - eng
GR  - P30 CA014520/CA/NCI NIH HHS/United States
PT  - Journal Article
PL  - England
TA  - Biochem Insights
JT  - Biochemistry insights
JID - 101549953
PMC - PMC3792586
MID - NIHMS518109
OTO - NOTNLM
OT  - TNF superfamily
OT  - cancer therapy
OT  - fusion protein
OT  - gene therapy
OT  - targeted delivery
OT  - tumor necrosis factor-alpha (TNF-alpha)
EDAT- 2008/07/22 00:00
MHDA- 2008/07/22 00:01
PMCR- 2013/10/08
CRDT- 2013/10/12 06:00
PHST- 2013/10/12 06:00 [entrez]
PHST- 2008/07/22 00:00 [pubmed]
PHST- 2008/07/22 00:01 [medline]
PHST- 2013/10/08 00:00 [pmc-release]
PST - ppublish
SO  - Biochem Insights. 2008 Jul 22;2008:15-21.